Sage Journals: Discover world-class research

Abstract

Background:

Bone marrow edema (BME) of the foot and ankle is challenging to treat. One approach is intravenous Iloprost treatment, which is a vasoactive prostacyclin analog. The aim of this study was to evaluate the early and intermediate outcome of intravenous Iloprost therapy on BME of the foot and ankle and to analyze the influence of its etiology and Association Research Circulation Osseous (ARCO) stage on the outcome.

Methods:

This was a retrospective study with prospective follow-up. All patients treated by intravenous Iloprost for BME of the foot and ankle (ARCO I-III) at a single orthopedic reference center were included. Demographics, medical history, and MRIs were assessed prior to treatment (t0). MRIs were used to assess the BMEs’ etiology (idiopathic/ischemic/metabolic, mechanical/degenerative, traumatic) and severity (ARCO). Complications as well as changes in pain, treatment, and MRI were evaluated after 3 months (t1). The following patient-rated outcome measures (PROMs) were assessed prospectively (t2): 12-Item Short Form Health Survey (SF-12), Visual Analog Scale Foot and Ankle (VAS FA), and the Foot Function Index (FFI) (also at t0). The descriptive outcomes and the influence of the etiology and ARCO on the outcome parameters were evaluated. Out of 70 eligible patients, 42 patients (60%; 47 ± 15 years; 30% female) with a mean follow-up of 28 ± 19 months were included.

Results:

Twelve patients reported minor complications during Iloprost therapy. At t1, pain decreased significantly in 56%, and the amount of BME decreased in 83% of patients. Both parameters correlated moderately (r = −0.463, P = .015). The PROMs at t2 revealed moderate results. The overall FFI improved from 59 ± 21 to 30 ± 22 (P < .001), the overall VAS FA was 68 ± 20, the SF-12 Physical Component Summary 42 ± 12 and Mental Component Summary 50 ± 9. Subgroup analysis revealed no significant influence of the etiology or ARCO stage on any outcome measure.

Conclusion:

Iloprost therapy for BME of the foot and ankle resulted in a 60% pain and 80% edema decrease after 3 months. After 2 years, patient-rated outcome measures showed residual impairment. Neither the etiology nor ARCO stage significantly influenced the outcome.

Level of Evidence:

Level III, comparative study.

Keywords

Ilomedin Iloprost bone marrow edema foot and ankle

Get full access to this article

View all access options for this article.

References

Aigner

Meizer

Meraner

Becker

Meizer

Landsiedl

Bone marrow edema syndrome in postpartal women: treatment with Iloprost. Orthop Clin North Am. 2009;40(2):241-247.

Aigner

Meizer

Stolz

, et al. Iloprost for the treatment of bone marrow edema in the hindfoot. Foot Ankle Clin. 2003;8(4):683-693.

Aigner

Petje

Steinboeck

Schneider

Krasny

Landsiedl

Treatment of bone-marrow oedema of the talus with the prostacyclin analogue Iloprost. An MRI-controlled investigation of a new method. J Bone Joint Surg Br. 2001;83(6):855-858.

Arazi

Yel

Uguz

Emlik

Be aware of bone marrow edema syndrome in ankle arthroscopy: a case successfully treated with Iloprost. Arthroscopy. 2006;22(8):909.e1-909.e3.

Baier

Schaumburger

Götz

, et al. Bisphosphonates or prostacyclin in the treatment of bone-marrow oedema syndrome of the knee and foot. Rheumatol Int. 2012;33(6):1397-1402.

Baumbach

Prall

Kramer

Braunstein

Böcker

Polzer

Functional treatment for fractures to the base of the 5th metatarsal—influence of fracture location and fracture characteristics. BMC Musculoskelet Disord. 2017;18(1):534.

Beckmann

Roth

Niethard

Mauch

Best

Maus

Bone marrow edema and atraumatic necrosis of the femoral head: therapy [in German]. Orthopäde. 2015;44(9):662-671.

Beckmann

Schmidt

Schaumburger

, et al. Infusion, core decompression, or infusion following core decompression in the treatment of bone edema syndrome and early avascular osteonecrosis of the femoral head. Rheumatol Int. 2013;33(6):1561-1565.

Budiman-Mak

Conrad

Roach

KE.

The Foot Function Index: a measure of foot pain and disability. J Clin Epidemiol. 1991;44(6):561-570.

10.

Claßen

Becker

Landgraeber

, et al. Long-term clinical results after Iloprost treatment for bone marrow edema and avascular necrosis. Orthop Rev (Pavia). 2016;8(1):6150.

11.

Craiovan

Baier

Grifka

Götz

Schaumburger

Beckmann

Bone marrow edema syndrome (BMES). Orthopäde. 2013;42(3):191-204.

12.

Hofmann

Kramer

Breitenseher

Aigner

Das schmerzhafte Knochenmarködem im Kniegelenk [Painful bone marrow edema in the knee joint]. Arthroskopie. 2003;16(2):88-101.

13.

Jäger

Zilkens

Bittersohl

, et al. Efficiency of Iloprost treatment for osseous malperfusion. Int Orthop. 2010;35(5):761-765.

14.

Martin

Irrgang

JJ.

A survey of self-reported outcome instruments for the foot and ankle. J Orthop Sports Phys Ther. 2007;37(2):72-84.

15.

Maurischat

Ehlebracht-König

Kühn

Bullinger

Structural validity of the Short Form 36 (SF-36) in patients with rheumatic diseases [in German]. Z Rheumatol. 2005;64(4):255-264.

16.

Mayerhoefer

Kramer

Breitenseher

, et al. MRI-demonstrated outcome of subchondral stress fractures of the knee after treatment with Iloprost or tramadol: observations in 14 patients. Clin J Sport Med. 2008;18(4):358-362.

17.

Mayerhoefer

Kramer

Breitenseher

, et al. Short-term outcome of painful bone marrow oedema of the knee following oral treatment with Iloprost or tramadol: results of an exploratory phase II study of 41 patients. Rheumatology. 2007;46(9):1460-1465.

18.

Mehlhorn

Zwingmann

Hirschmüller

Südkamp

Schmal

Radiographic classification for fractures of the fifth metatarsal base. Skeletal Radiol. 2014;43(4):467-474.

19.

Meier

Kraenzlin

Friederich

, et al. Effect of ibandronate on spontaneous osteonecrosis of the knee: a randomized, double-blind, placebo-controlled trial. Osteoporos Int. 2014;25(1):359-366.

20.

Meizer

Radda

Stolz

, et al. MRT-verifizierte Analyse von 104 mit Iloprost behandelten Patienten mit Knochenmarködemen unterschiedlicher Lokalisation [MRI-controlled analysis of 104 patients with painful bone marrow edema in different joint localizations treated with the prostacyclin analogue iloprost]. Wien Klin Wochenschr. 2005;117(7-8):278-286.

21.

Mirghasemi

Trepman

Sadeghi

Rahimi

Rashidinia

Bone marrow edema syndrome in the foot and ankle. Foot Ankle Int. 2016;37(12):1364-1373.

22.

Müller

Schedel

Schneller

, et al. Initial nuclear magnetic resonance tomography results of the treatment course of avascular femur head necrosis after femoral core decompression [in German]. Aktuelle Radiol. 1997;7(2):79-85.

23.

Richter

Zech

Geerling

Frink

Knobloch

Krettek

A new foot and ankle outcome score: questionnaire based, subjective, visual-analogue-scale, validated and computerized. Foot Ankle Surg. 2006;12(4):191-199.

24.

Röhner

Zippelius

Steindl

Fussi

Perka

Effects of intravenous Iloprost therapy in patients with bone marrow oedema of the foot and ankle. Eur J Orthop Surg Traumatol. 2014;24(8):1609-1616.

25.

Roth

Beckmann

Bohndorf

, et al. S3-Guideline non-traumatic adult femoral head necrosis. Arch Orthop Trauma Surg. 2016;136(2):165-174.

26.

Schmitt-Sody

Kirchhoff

Mayer

Goebel

Jansson

Avascular necrosis of the femoral head: inter- and intraobserver variations of Ficat and ARCO classifications. Int Orthop. 2008;32(3):283-287.

27.

Schneider

Jurenitsch

Age- and sex-related normative data for the Foot Function Index in a German-speaking cohort. Foot Ankle Int. 2016;37(11):1238-1242.

28.

Singh

Ferrero

Rose

Goldberg

Cullen

Bone marrow edema syndrome of the foot and ankle: mid- to long-term follow-up in 18 patients. Foot Ankle Spec. 2016;9(3):218-226.

29.

Stüber

Zech

Bay

Qazzaz

Richter

Normative data of the Visual Analogue Scale Foot and Ankle (VAS FA) for pathological conditions. Foot Ankle Surg. 2011;17(3):166-172.

30.

Tonbul

Guzelant

Gonen

Baca

Ozbaydar

MU.

Relationship between the size of bone marrow edema of the talus and ankle pain. J Am Podiatr Med Assoc. 2011;101(5):430-436.

31.

Unay

Poyanli

Akan

Guven

Demircay

The relationship between bone marrow edema size and knee pain. Knee Surg Sports Traumatol Arthrosc. 2009;17(11):1298-1304.

32.

Zanetti

Steiner

Seifert

Hodler

Clinical outcome of edema-like bone marrow abnormalities of the foot. Radiology. 2002;222(1):184-188.

33.

Zarzaur

Kozar

Fabian

Coimbra

A survey of American Association for the Surgery of Trauma member practices in the management of blunt splenic injury. J Trauma. 2011;70(5):1026-1031.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.27 MB

Treatment of Bone Marrow Edema of the Foot and Ankle With the Prostacyclin Analog Iloprost

Abstract

Background:

Methods:

Results:

Conclusion:

Level of Evidence:

Keywords

Get full access to this article

References

Supplementary Material